alpha labs retatrutide (RETA) – Research Peptide Retatrutide (GLP-3) Research Peptide |

Rare in the trials, but a recognised concern with GLP-1 medications generally, partly because rapid weight loss itself can trigger gallstones

Kailera plans to begin global Phase 3 trials of HRS9531 as KAI-9531 evaluating multiple doses, including 8 mg and 10 mg, and longer treatment durations by year-end 2025

Kidney issues Dehydration related to nausea, vomiting, or diarrhea can sometimes lead to kidney problems while using GLP-1 drops

Gastric emptying is more rapid in adolescents with Type 1 diabetes and impacts on postprandial glycemia

This approach supports muscle retention and minimizes side effects

Several groups have designed monomeric dual and triple agonists based on the interactions of GLP-1 with glucagon 54,55,56 and/or GIP 57,58,59